目的：探讨替格瑞洛致不良反应（ADR）的一般规律和特点，为临床合理用药提供参考。方法：随访我院2013年12月－2015年6月间使用替格瑞洛的患者672例，对其服药后的ADR情况进行分析、总结。结果：参与调查的672例患者共有78例（11.6％）发生了108例次ADR，男女比例为5.5∶1，差异有统计学意义（P＜0.05）；51～60岁患者最多（37.2％）；主要累及器官/系统为呼吸系统（41.7％）和皮肤及其附件（38.0％），主要临床表现为轻微出血（78.7％）、呼吸困难（17.6％）和心跳减慢（2.8％）等；未发现严重的ADR。结论：替格瑞洛具有良好的安全性和耐受性，但由于其上市时间较短，且在亚洲人群中缺少大规模的临床试验的循证医学证据，临床应加强用药监测，减少ADR发生，确保用药安全。%OBJECTIVE:To explore the general regulation and characteristics of adverse drug reactions(ADR)induced by ti-cagrelor,and provide reference for clinical rational drug use. METHODS:672 patients received ticagrelor in our hospital from Dec. 2013 to Jun. 2015 were followed-up,and the situation was analyzed and summarized after taking drug. RESULTS:In the 672 patients,78(11.6%)patients sutfered from 108 cases of ADR,the ratio of male to female was 5.5∶1,there was statistical signifi-cance (P<0.05);patients mostly aged 51-60 years (37.2%);the mainly involved organs/systems were respiratory system (41.7%),and skin and its appendages (38.0%),the main clinical manifestations were minor bleeding (78.7%),dyspnea (17.6%) and bradycardia (2.8%);no severe ADR was found. CONCLUSIONS:Ticagrelor had good safety and tolerability,but due to its shorter time to market in China and absense of evidence-based medicine for large-scale clinical trials in Asian population, clinic should strengthen medication monitoring to reduce the ADR and ensure drug safety.
展开▼
